-
Company Profile
![]()
Pelican Inc – Company Profile
Pelican Inc (Pelican) formerly Pfenex Inc is a clinical-stage development and licensing biotechnology company focused on developing protein-based therapeutics including vaccines, biologics and biosimilars. The company’s pipeline products comprise PF708, a teriparatide drug candidate to treat osteoporosis; novel anthrax vaccine candidates such as Px563L and RPA563; biosimilar product candidates including PF582 to Lucentis; PF529 to Neulasta; and PF690 to Oncaspar. The company utilizes its Pfenex expression technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and...
Add to Basket -
Product Insights
![]()
Anthrax Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Anthrax Global Clinical Trials Review, H2, 2018" provides an overview of Anthrax clinical trials scenario. This report provides top line data relating to the clinical trials on Anthrax. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
![]()
Anthrax Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Anthrax Global Clinical Trials Review, H2, 2016" provides an overview of Anthrax clinical trials scenario. This report provides top line data relating to the clinical trials on Anthrax. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.